anti-inflammatory therapies for COVID-19: living meta-analysis of clinical studies

Table Graph

anti-inflammatory therapies - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
death D28	0.99 [0.94, 1.06]	< 1	3%	8 studies (8/-)	56.7 %	some concern	serious	moderate	crucial	-
death or transfer to ICU	0.83 [0.35, 1.95]	< 1	0%	1 study (1/-)	66.5 %	NA	not evaluable		crucial	-
deaths	0.99 [0.94, 1.05]	< 1	0%	12 studies (12/-)	57.1 %	some concern	critical	moderate	crucial	-
deaths (time to event analysis only)	0.42 [0.06, 2.87]	< 1	72%	2 studies (2/-)	81.1 %	some concern	not evaluable	moderate	crucial	-
clinical deterioration	0.18 [0.05, 0.57]	< 1	14%	4 studies (4/-)	99.8 %	some concern	not evaluable	moderate	important	-
clinical improvement	10.27 [1.17, 90.18]	> 1	0%	1 study (1/-)	98.2 %	NA	not evaluable		important	-
clinical improvement (14-day)	10.27 [1.17, 90.18]	> 1	0%	1 study (1/-)	98.2 %	NA	not evaluable		important	-
clinical improvement (28-day)	3.68 [0.18, 75.54]	> 1	0%	1 study (1/-)	79.8 %	NA	not evaluable		important	-
clinical improvement (7-day)	6.72 [1.50, 30.07]	> 1	0%	1 study (1/-)	99.4 %	NA	not evaluable		important	-
death or ventilation	0.94 [0.78, 1.15]	< 1	70%	2 studies (2/-)	71.9 %	some concern	not evaluable	moderate	important	-
hospital discharge	0.98 [0.94, 1.03]	> 1	0%	2 studies (2/-)	21.5 %	some concern	not evaluable	moderate	important	-
mechanical ventilation	0.94 [0.76, 1.15]	< 1	34%	5 studies (5/-)	73.1 %	some concern	serious	moderate	important	-
radiologic improvement (14-day)	2.87 [1.56, 5.28]	> 1	0%	1 study (1/-)	100.0 %	NA	not evaluable		important	-
viral clearance	1.71 [0.80, 3.64]	> 1	0%	1 study (1/-)	91.7 %	NA	not evaluable		important	-
viral clearance by day 7	1.71 [0.80, 3.64]	> 1	0%	1 study (1/-)	91.7 %	NA	not evaluable		important	-
ICU admission	0.93 [0.55, 1.57]	< 1	0%	3 studies (3/-)	61.1 %	some concern	not evaluable	moderate	non important	-
recovery	3.46 [1.05, 11.35]	> 1	0%	1 study (1/-)	97.9 %	NA	not evaluable		non important	-
safety endpoints 00
serious adverse events	0.19 [0.04, 0.84]	< 1	0%	3 studies (3/-)	98.6 %	some concern	not evaluable	moderate	important	-
adverse events	1.24 [0.77, 2.00]	< 1	0%	6 studies (6/-)	19.2 %	low	not evaluable	high	non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

anti-inflammatory therapies - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00